News Articles
Latest articles, insights, and updates from the blog.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.
Faster TRD Remission Hinges on Measurement and Dose Timing
New analysis in Psychiatric Times shows that symptom tracking and rapid dose adjustment drive faster remission in TRD, here's what it means for ketamine care.
What Side Effect Data Tells Us About Ketamine Dosing
New analysis of NMDA receptor antagonist side effects in treatment-resistant depression underscores why dose optimization and early monitoring matter.
NMDA Antagonist Side Effects: What the Data Says
New clinical analysis examines why patients stop ketamine and esketamine treatment, and what smarter monitoring can do to keep them on track.
NRx FDA Review: Preservative-Free Ketamine Moves Forward
NRx Pharmaceuticals reports progress on its FDA application for preservative-free ketamine. Here's what the formulation difference means for low-dose patients.
Trump EO on Psychedelics: What It Means for Ketamine
President Trump's April 2026 executive order accelerating psychedelic research may reshape ketamine's regulatory and clinical landscape. Here's what we know.
NRx Moves Closer to FDA-Approved Preservative-Free Ketamine
NRx Pharmaceuticals signals FDA review progress on its preservative-free ketamine application. What this means for patients and clinicians in 2026.
Why Clinicians Are Pushing Harder on TRD Goals
New clinical thinking on treatment-resistant depression pushes toward true remission, not just symptom reduction. Here's what it means for ketamine patients.
Ketamine Side Effects & When to Switch: New Clinical Guidance
New clinical guidance urges tracking PHQ-9 scores, monitoring side effects closely, and switching NMDA treatments sooner to reach remission faster.
Rethinking Treatment-Resistant Depression Care in 2026
New clinical perspectives on treatment-resistant depression push for true remission over symptom reduction. Here's what it means for ketamine patients.
Psychedelics Executive Order: What It Means for Ketamine
A new executive order targets psychedelic medicine access. Here's what the policy shift means for low-dose ketamine patients and providers in 2026.
NMDA Antagonist Side Effects: What the Data Now Shows
Psychiatric Times reviews side effect profiles and dropout rates for NMDA antagonists like ketamine. Here's what it means for low-dose ketamine patients.
Insurance Gaps in Ketamine Care, And One Fix
Most health insurers deny coverage for ketamine depression treatment in 2026. Here's what that means for patients and how access gaps are being bridged.